We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

HBAN:NASDAQHuntington Bancshares Incorporated Analysis

Data as of 2026-03-10 - not real-time

$16.12

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Huntington Bancshares (HBAN) trades at $16.12, sitting below its 20‑day ($17.33) and 50‑day ($17.68) moving averages, with a RSI of 34.6 and a bearish MACD that suggest short‑term pressure, yet the stock remains comfortably above the identified support at $15.58. Fundamentally, the bank shows solid performance: revenue grew 10.3% YoY, operating margin stands at 39.8% and profit margin at 28.7%, while the P/E of 11.6 is well under the industry average of 17.4, indicating relative value. The dividend yield of 3.85% with a payout ratio of 44.6% appears sustainable, supported by positive operating cash flow and a strong cash position. Analyst sentiment is upbeat – the consensus recommendation is “Buy” with a median price target of $21 and a Morgan Stanley upgrade to $23, highlighting the stock’s upside potential of roughly 28% from the current level. Despite a 30‑day volatility of 34% and a beta above 1, the company’s regional focus, solid balance sheet, and dividend appeal mitigate broader market risks. In sum, HBAN presents a blend of value and growth characteristics, offering a compelling entry point for investors willing to navigate near‑term technical softness.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price below short‑term moving averages and bearish MACD
  • RSI nearing oversold territory offering potential bounce
  • Attractive dividend yield provides downside cushion

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Revenue growth of 10% and strong operating margins
  • Valuation metrics (P/E, DCF) suggest upside to analyst targets
  • Analyst upgrades and raised price targets reinforce confidence

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Sustainable dividend with moderate payout ratio
  • Robust cash generation and manageable leverage
  • Long‑term upside potential to $20‑$21 target price

Key Metrics & Analysis

Financial Health

Revenue Growth10.30%
Profit Margin28.74%
P/E Ratio11.6
ROE10.10%
ROA1.04%
P/B Ratio1.2
Op. Cash Flow$2.5B
Industry P/E17.4

Technical Analysis

TrendNeutral
RSI34.6
Support$15.58
Resistance$19.26
MA 20$17.33
MA 50$17.68
MA 200$16.85
MACDBearish
VolumeStable
Fear & Greed Index76.57

Valuation

Fair Value$15.91
Target Price$20.64
Upside/Downside28.06%
GradeFair
TypeBlend
Dividend Yield3.85%

Risk Assessment

Beta1.14
Volatility33.98%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.